β-(1-indanyl)propionic acid | 55288-83-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: β-(1-indanyl)propionic acid
• 英文别名: 3-Indan-1-yl-propionsaeure；β-(Indanyl-1)-propionsaeure；3-(1-Indanyl)propansaeure；3-(indan-1-yl)propionic acid；β-(Hydrindyl-(1))-propionsaeure；Hydrinden-(β-propionsaeure)-(1)；2-carboxyethylindane；3-(2,3-dihydro-1H-inden-1-yl)propanoic acid
• CAS: 55288-83-0
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: UCKWJLDPHMBXEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  β-(1-indanyl)propionic acid 在 甲酸 、 PPA 、 锌 作用下， 反应 2.0h， 生成 Acenaphthen-5-yl-essigsaeure
  参考文献：
  名称：

  Bisagni,E. et al., Bulletin de la Societe Chimique de France, 1970, p. 3023 - 3031

  摘要：

  DOI：
• 作为产物：
  描述：

  3-茚-3-基-丙酸 在 palladium on activated charcoal 、 乙醇 作用下， 生成 β-(1-indanyl)propionic acid
  参考文献：
  名称：

  Posthysterectomy Vault Eversion with a Large Retroperitoneal Mass

  摘要：

  A woman with complete vaginal eversion was found to have a large pelvic mass, extending from the rectovaginal septum to the presacral space. This 66-year-old woman with posthysterectomy vaginal eversion complained of pelvic fullness. A pessary provided relief of the prolapse, but the symptom of fullness persisted. Physical examination did not identify a pelvic mass. Computed tomography (CT) and magnetic resonance imaging (MRI) demonstrated a 9 cm tumor of the rectovaginal septum, extending to the presacral space. At laparotomy the patient had a massive neurofibroma arising from the anterior rectal wall. This case is of interest because the complete vaginal prolapse obscured the diagnosis of this large pelvic tumor. CT and MRI were useful in identifying and characterizing the mass. To our knowledge, this is the first reported case of vaginal prolapse with a large pelvic mass.

  DOI：

  10.1007/pl00004038

文献信息

• Glutamate receptor antagonists: fused cycloalkylouinoxalinediones
  申请人：Warner-Lambert Company

  公开号：US05721234A1

  公开（公告）日：1998-02-24

  Novel glutamate receptor antagonists represented by the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein Z is an alicyclic fused ring having 5 to 7 carbon atoms; R.sup.1 is hydrogen, an alkyl or an arylalkyl; and A is O, CH.sub.2, NR.sup.4, CH.sub.2 NR.sup.4, CN, tetrazole or CO wherein R.sup.4 is hydrogen, alkyl, hydroxyalkyl, aminoalkyl or aralkyl, wherein (i) when A is O, CH.sub.2, NR.sup.4 or CH.sub.2 NR.sup.4 then B is hydrogen, alkyl, alkenyl, alkynyl, aryl, aralkyl, hydroxyalkyl, alkoxy, aminoalkyl, heterocyclic, alkylheterocyclic, heterocyclic-methyl, heterocyclic-ethyl, alkylcarbonyl, cycloalkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heterocyclic-carbonyl, alkylheterocyclic-carbonyl, or when A is NR.sup.4 or CH.sub.2 NR.sup.4 then B is a naturally occurring .alpha.-amino acid moiety joined by an amide bond or B joins with R.sup.4 and the nitrogen to form a four to seven membered heterocyclic ring, provided that when Z is a fused cyclohexyl ring and R.sup.4 is hydrogen then B is not hydrogen; (ii) when A is CN then B is not present and Z is not a fused cyclohexyl ring; (iii) when A is tetrazole then B is hydrogen or alkyl having 1 to 6 carbon atoms; and (iv) when A is CO then B is hydroxy, alkoxy, aralkoxy, alkyl having 1 to 6 carbon atoms, aralkyl, NR.sup.7 R.sup.8.

  新型谷氨酸受体拮抗剂的化学式为##STR1##或其药用盐，其中Z是一个具有5到7个碳原子的脂环融合环；R.sup.1是氢、烷基或芳基烷基；A是O、CH.sub.2、NR.sup.4、CH.sub.2 NR.sup.4、CN、四唑或CO，其中R.sup.4是氢、烷基、羟基烷基、氨基烷基或芳基烷基，其中(i)当A为O、CH.sub.2、NR.sup.4或CH.sub.2 NR.sup.4时，B是氢、烷基、烯基、炔基、芳基、芳基烷基、羟基烷基、烷氧基、氨基烷基、杂环、烷基杂环、杂环甲基、杂环乙基、烷基羰基、环烷基羰基、芳基羰基、芳基烷基羰基、杂环羰基、烷基杂环羰基，或当A为NR.sup.4或CH.sub.2 NR.sup.4时，B是通过酰胺键连接的天然存在的α-氨基酸基团或B与R.sup.4和氮形成四到七元杂环，前提是当Z是融合的环己基环且R.sup.4是氢时，B不是氢；(ii)当A为CN时，B不存在且Z不是融合的环己基环；(iii)当A为四唑时，B是氢或具有1到6个碳原子的烷基；(iv)当A为CO时，B是羟基、烷氧基、芳基烷氧基、具有1到6个碳原子的烷基、芳基烷基或NR.sup.7 R.sup.8。
• 1,4-disubstituted piperazines
  申请人：Adir et Compagnie

  公开号：US05194437A1

  公开（公告）日：1993-03-16

  The compounds are 1,4-disubstituted piperazines useful for the treatment of disorders of central nervous system and neuroendocrine disorders. A compound disclosed is (R,S)-4-(benzodioxan-5-yl)-1-[(benzocyclobutan-1-yl)methyl]piperazine.

  这些化合物是用于治疗中枢神经系统和神经内分泌紊乱的1,4-二取代哌嗪类化合物。其中一种化合物是(R,S)-4-(苯并二氧杂苯-5-基)-1-[(苯并环丁-1-基)甲基]哌嗪。
• 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same
  申请人：Fujii Akihito

  公开号：US20050171196A1

  公开（公告）日：2005-08-04

  The present invention provides 2-furancarboxylic acid hydrazide compounds represented by General Formula (I) below, and prodrugs, physiologically acceptable salts, hydrates, solvates thereof, methods for producing them and pharmaceutical compositions containing them: wherein A is a group represented by Formula (a) or the like: (wherein either R 4 or R 5 represents cyano, nitro or the like, and the other represents a hydrogen atom or the like); either R 1 or R 2 represents a group: -D-(X)m-R 6 or the like, and the other represents a group: -E-(Y)n-R 7 , hydrogen atom, aryl or the like; R 3 is a hydrogen atom or the like; D and E independently represent aryl; X and Y independently represent O or the like; R 6 and R 7 independently represent alkyl, aryl, arylalkyl or the like; and m and n are independently 0 or 1, provided that the aryl is optionally substituted. Such compounds exhibit a potent antagonistic activity on glucagon receptor and are of use as preventive and/or therapeutic agents for symptoms and diseases in which glucagon is involved.

  本发明提供了由下列通式（I）表示的2-呋喃羧酸肼化合物，以及它们的前药、生理上可接受的盐、水合物、溶剂化物、制备方法和含有它们的制药组合物：其中A是由式（a）或类似式表示的基团：（其中R4或R5代表氰基、硝基或类似物，另一个代表氢原子或类似物）；R1或R2代表基团：-D-(X)m-R6或类似物，另一个代表基团：-E-(Y)n-R7、氢原子、芳基或类似物；R3是氢原子或类似物；D和E独立地表示芳基；X和Y独立地表示O或类似物；R6和R7独立地表示烷基、芳基、芳基烷基或类似物；m和n独立地表示0或1，但芳基可选择性地被取代。这些化合物表现出强大的胰高血糖素受体拮抗活性，并且可用作预防和/或治疗胰高血糖素参与的症状和疾病的药物。
• HELICENE DERIVATIVE, AXIALLY ASYMMETRIC AMINO ACID, AMINE OR AMINOALCOHOL DERIVATIVE, PERYLENE DERIVATIVE OR SALT THEREOF, AND METHODS FOR PRODUCING SAME
  申请人：Furuta Takumi

  公开号：US20110251393A1

  公开（公告）日：2011-10-13

  The invention provides a helicene derivative, axially chiral amino acid, amine or amino alcohol derivative, and azaperylene, such as compounds represented by Formulae (I), (I′), (II), (II′), and (III): and a method for producing the same.

  本发明提供了螺环衍生物，轴向手性氨基酸，胺或氨基醇衍生物和氮杂蒽衍生物，例如由公式（I），（I'），（II），（II'）和（III）表示的化合物以及其制备方法。
• PEPTIDIC COMPOUND AND USE OF SAME
  申请人：Suenaga Kiyotake

  公开号：US20120122797A1

  公开（公告）日：2012-05-17

  An object of the present invention is to provide a novel compound having an antitumor/anticancer effect. Specifically, the present invention provides a compound represented by Formula (I), a derivative thereof or a salt of the same. In Formula (I), R 1 represents an alkyl group, an alkenyl group, a cycloalkyl group, an amino group, a monoalkylamino group, a dialkylamino group, an aryl group, a heteroaryl group, an aralkyl group or an alkoxy group; R 2 represents a substituted or unsubstituted amino group or a substituted or unsubstituted nitrogen-containing heterocyclic group; and R 3 represents hydrogen, halogen, alkyl, methoxy, cyano, trifluoromethyl, acetylamino or amino. In Formula (I), N-Me-Ala may be substituted with N-Me-Gly, N-Me-Ser, N-Me-Thr, Ala, Gly, Ser or Thr; N-Me-Phe may be substituted with Phe, Tyr or N-Me-Tyr; and D-Leu may be substituted with L-Leu.

  本发明的目的是提供一种具有抗肿瘤/抗癌作用的新化合物。具体而言，本发明提供由式（I）表示的化合物，其衍生物或其盐。在式（I）中，R1表示烷基，烯基，环烷基，氨基，单烷基氨基，双烷基氨基，芳基，杂环芳基，芳基烷基或烷氧基；R2表示取代或未取代的氨基或取代或未取代的含氮杂环基；R3表示氢，卤素，烷基，甲氧基，氰基，三氟甲基，乙酰氨基或氨基。在式（I）中，N-Me-Ala可以被N-Me-Gly，N-Me-Ser，N-Me-Thr，Ala，Gly，Ser或Thr替代；N-Me-Phe可以被Phe，Tyr或N-Me-Tyr替代；D-Leu可以被L-Leu替代。